Latest news:
Primary Class: Inebriant / Dependency / Illegal Drugs
Alkermes, Inc. (NASDAQ: ALKS) nowadays proclaimed the publishing of two new studies in the June publication of The American Journal of Managed Aid 1,2 evaluating pharmacoeconomic information on dependence treatments, including VIVITROL ® ( naltrexone for extended-release injectable abatement), with the terminus of totality healthcare costs. The get-go paper1 showed that patients receiving an FDA-approved medicine for their inebriant dependency had rock-bottom sum healthcare costs, including inmate, outpatient and pharmaceutics costs, compared to patients toughened without medicine. Patients tempered with VIVITROL had importantly lour infirmary costs, slaked and fewer admissions to the infirmary than patients toughened with any of leash early medications: viva naltrexone, antabuse or acamprosate. The indorsement paper2 evaluated patients hardened for opioid addiction and again showed that discourse with an FDA-approved medicament rock-bottom tally healthcare costs, with VIVITROL-treated patients experiencing fewer hospitalizations than patients toughened with the viva medications buprenorphine, viva naltrexone and fixer. In summation, disdain higher drugstore costs for VIVITROL, the aggregate healthcare costs for VIVITROL were no greater than buprenorphine or unwritten naltrexone, and were 49% lour than methadon.
(more…)